Bristol Myers Squibb Receives European Commission Approval of CAMZYOS® (mavacamten), for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
PRINCETON, N.J.--(BUSINESS WIRE)--Jun 26, 2023--
Source: joplinglobe.com
Meyer Children News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Meyer Children. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Meyer Children Today - Breaking & Trending Today
Bristol Myers Squibb Receives European Commission Approval of CAMZYOS® (mavacamten), for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
CAMZYOS is the first and only cardiac myosin inhibitor approved in the European Union Approval based on two positive Phase 3 trials, EXPLORER-HCM and VALOR-HCM, demonstrating significant benefit in patients treated with CAMZYOS versus placebo
Source: marketscreener.com
International School of Florence annual gala held at Stazione Leopolda
The International School of Florence held its annual philanthropic gala on May 12 at Stazione Leopolda.
Source: theflorentine.net
Joseph's fundraising fight for life changing bowel surgery
A FAMILY is currently fundraising to send their child abroad for a “better chance of life”.
Source: wirralglobe.co.uk
Simplified drug provocation test assesses nonimmediate amoxicillin reactions in children
A single therapeutic dose administered on the first day of a drug provocation test could be safe in diagnosing mild nonimmediate reactions to amoxicillin-clavulanic acid, according to a study published in Pediatric Allergy and Immunology. This single dose would save time because patients would spend less time in the hospital, Giulia Liccioli, MD, of the allergy unit in the department of
Source: healio.com